Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AbCellera Biologics Inc. (ABCL)

11.01   0.25 (2.32%) 02-02 16:00
Open: 10.92 Pre. Close: 10.76
High: 11.11 Low: 10.82
Volume: 1,288,641 Market Cap: 3,150(M)

Technical analysis

as of: 2023-02-02 4:28:29 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 12.97     One year: 15.15
Support: Support1: 9.82    Support2: 9.02
Resistance: Resistance1: 11.1    Resistance2: 12.97
Pivot: 10.45
Moving Average: MA(5): 10.71     MA(20): 10.22
MA(100): 11.03     MA(250): 10.12
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 90.1     %D(3): 87.2
RSI: RSI(14): 59.4
52-week: High: 14.97  Low: 5.42
Average Vol(K): 3-Month: 1,921 (K)  10-Days: 1,128 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ABCL ] has closed It is unclear right now based on current values. 61.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.12 - 11.17 11.17 - 11.21
Low: 10.71 - 10.76 10.76 - 10.81
Close: 10.93 - 11.01 11.01 - 11.08

Company Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Headline News

Thu, 02 Feb 2023
The 7 Most Undervalued Biotech Stocks to Buy in February 2023 - InvestorsObserver

Thu, 02 Feb 2023
Aditya Birla Capitals Q3 net up 27% YoY as retail, SME lending grows - Business Standard

Tue, 24 Jan 2023
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock? - Nasdaq

Sun, 22 Jan 2023
Allspring Global Investments Holdings LLC Buys Shares of 116434 ... - MarketBeat

Sat, 21 Jan 2023
AbCellera Biologics Stock: Here’s What’s Coming in 2023 - Yahoo Canada Finance

Fri, 20 Jan 2023
Health Care Sector Update for 01/20/2023: LLY, ABCL, BLI, TNYA ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 286 (M)
% Held by Insiders 2.0808e+008 (%)
% Held by Institutions 28.7 (%)
Shares Short 15,350 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 3.5387e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 41.1
Operating Margin (%) 55.6
Return on Assets (ttm) 15.3
Return on Equity (ttm) 22.5
Qtrly Rev. Growth 1
Gross Profit (p.s.) 0.95
Sales Per Share 1.73
EBITDA (p.s.) 1.01
Qtrly Earnings Growth 0.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow 230 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 1.6
Price to Book value 0
Price to Sales 6.33
Price to Cash Flow -0.61

Stock Dividends

Dividend 0
Forward Dividend 1.968e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.